American Vietnamese Biotech

American Vietnamese Biotech EBITDA per Share

The EBITDA per Share of American Vietnamese Biotech (AMV.VN) as of Nov 3, 2026 is -14.26 VND. In the previous year, EBITDA per Share was 248.18 VND — a change of -105.75% (lower).

EBITDA per Share

-14.26VND

YoY

-105.75%

Last updated:

EBITDA per Share of American Vietnamese Biotech is 2024 -14.26 VND. EBITDA per Share of American Vietnamese Biotech was 2023 248.18 VND. It decreases by -105.75% lower compared to the previous year.

The American Vietnamese Biotech EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
1,307.22 VND
Jan 1, 2018
4,003.57 VND
Jan 1, 2019
4,081.55 VND
Jan 1, 2020
1,257.49 VND
Jan 1, 2021
1,083.04 VND
Jan 1, 2022
592.82 VND
Jan 1, 2023
248.18 VND
Jan 1, 2024
-14.26 VND
The American Vietnamese Biotech EBITDA per Share history
YEAREBITDA per ShareYoY
-14.26VND-105.75%
248.18VND-58.14%
592.82VND-45.26%
1,083.04VND-13.87%
1,257.49VND-69.19%
4,081.55VND+1.95%
4,003.57VND+206.27%
1,307.22VND+70.95%
764.69VND+402.55%
152.16VND-114.50%
-1,049.50VND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Vietnamese Biotech Stock analysis

What does American Vietnamese Biotech do? American Vietnamese Biotech, Inc. generates revenue through the manufacture and distribution of high-tech medical diagnostics devices and equipment, including rapid diagnostic tests and ELISA kits. The company also produces medicines, vaccines, biological products, and cosmetic, soap, detergent, and cleaning products. Its subsidiary, American - Vietnamese Biology Company Limited, supports these manufacturing operations. The primary buyers are healthcare providers, laboratories, and distributors within the medical and pharmaceutical sectors, as well as consumers purchasing personal care items. The firm's financial investment activities and real estate trading contribute to additional revenue streams, though these are secondary to its core medical product manufacturing. The company's product portfolio targets both B2B segments in healthcare and B2C segments for consumer goods, with a focus on diagnostic tools and personal care solutions. As of 2012, the subsidiary structure remains central to its operational model. American Vietnamese Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Vietnamese Biotech stock

EBITDA per Share of American Vietnamese Biotech is -14.26 VND in 2024.

EBITDA per Share of American Vietnamese Biotech changed from 248.18 VND to -14.26 VND, representing a -105.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share American Vietnamese Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — American Vietnamese Biotech

All Key Metrics — American Vietnamese Biotech